

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Capiwasertib inhibits which of the following targets?
 - a. AKT
 - b. ESR1
 - c. PI3K
 - d. TROP2
2. Which of the following best describes outcomes with adjuvant abemaciclib relative to Ki-67 score in patients with high-risk HR-positive, HER2-negative early breast cancer in cohort 1 of the Phase III monarchE trial?
 - a. High Ki-67 correlated with better outcomes
 - b. Low Ki-67 correlated with better outcomes
 - c. Similar outcomes were observed regardless of Ki-67 index score
 - d. TROP2
3. Which of the following is the target of datopotamab deruxtecan?
 - a. NRG1
 - b. MET
 - c. CEACAM5
 - d. TROP2
4. The Exploratory Breast Lead Interval Study (EBLIS) revealed that a negative ctDNA test correlated with a significant improvement in which of the following for patients with breast cancer?
 - a. Relapse-free survival
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
5. The HER2CLIMB trial evaluated trastuzumab/tucatinib/capecitabine for patients with pretreated HER2-positive metastatic breast cancer and which of the following?
 - a. Previously treated stable brain metastases
 - b. Previously treated progressive brain metastases
 - c. Previously untreated brain metastases
 - d. All of the above